Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
Titel:
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
Auteur:
Richards, D.A. Boehm, K.A. Waterhouse, D.M. Wagener, D.J. Krishnamurthi, S.S. Rosemurgy, A. Grove, W. Macdonald, K. Gulyas, S. Clark, M. Dasse, K.D.